<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540745</url>
  </required_header>
  <id_info>
    <org_study_id>1712118546</org_study_id>
    <nct_id>NCT03540745</nct_id>
  </id_info>
  <brief_title>Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Nexalin Electrical Brain Stimulation as an Adjunctive Therapy for Substance Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carrier Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical
      Stimulation (TES) is a viable adjunctive treatment of substance use treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized Controlled Trial with block randomization. Inpatient subjects actively seeking
      substance abuse treatment at the Carrier Clinic who are diagnosed with a substance use
      disorder, including alcohol use disorder, tobacco use disorder, polysubstance use disorder,
      or other substance use disorder.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial with block randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All participants and investigators are blind to condition</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response</measure>
    <time_frame>5-8 Days</time_frame>
    <description>Reduction in depressive symptoms as a result of Nexalin vs Sham</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <condition>Insomnia</condition>
  <condition>Substance Abuse</condition>
  <arm_group>
    <arm_group_label>TES Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Where subject is randomized to TES.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TES-SHAM Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Where subject is randomized to a SHAM condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TES Treatment</intervention_name>
    <description>Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES</description>
    <arm_group_label>TES Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TES-SHAM Treatment</intervention_name>
    <description>Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES</description>
    <arm_group_label>TES-SHAM Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be able to provide informed consent, assessed by the study clinician

          2. Be able to speak, read and write fluently in English, assessed by the study clinician

          3. Be committed to completion of the study. The subject will need to attest to
             availability for 10 to 15 treatments over a 5 to 8 day period for the treatment
             protocol.

          4. Be adults over age 18 and under age 65

          5. Be actively receiving substance use treatment for a substance use disorder

        Exclusion Criteria:

          1. Pregnant or at risk of becoming pregnant

          2. Individual has a condition the Investigator believes would interfere with his or her
             ability to provide informed consent, comply with the study protocol, might confound
             the interpretation of the study results, or put the person at undue risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Grandner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carrier Clinic</name>
      <address>
        <city>Belle Mead</city>
        <state>New Jersey</state>
        <zip>08502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Michael A. Grandner</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry, Psychology, and Medicine Director, Sleep &amp; Health Research Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

